


















Introduction. One of the most severe diffuse liver diseases is chronic viral hepatitis C (CHC) combined with non-alcoholic fatty 
liver disease (NAFLD). After completing the treatment of CHC with drugs of direct antiviral action, there remains a high risk of 
further progression of liver fibrosis associated with the presence of comorbid pathology - NAFLD in patients. The above 
circumstances initiated us to search for new non-drug technologies to treat this category of patients. Purpose of the work: to study 
the effectiveness of use bentonite suspension in rats with a model of NAFLD and to substantiate the practicality of using bentonite 
in the complex treatment of CHC patients with concomitant NAFLD. Methods: experimental, anamnestic and clinical, general 
clinical, biochemical, determination of the HOMA index, leptin and adiponectin levels, ultrasonographic studies of the digestive 
system, bacteriological examination of feces, statistical methods.Results: According to microscopic examination, bentonite 
application in animals with the NAFLC model leads to a decrease in liver steatosis, restoration of bile formation and bile secretion, 
and protein-synthesizing liver function. In the blood, there was a positive dynamics to the restoration of energy-dependent 
transmembrane ion transport according to the activity of Na+/K+ -ATPase and Mg2+/Ca2+ -ATPase (in the liver tissue) and the 
balance of the antioxidant system (to restrain malondialdehyde and catalase activity). We examined 40 patients with CHC with 
concomitant NAFLD, who completed the course of antiviral therapy (AVT) and were divided into two groups. 1 (control) group (20 
people) received a basic treatment complex (diet therapy, which corresponded to the Mediterranean diet, a regimen of dosed 
physical exertion, patients of 2 groups (20 people, the main group) additionally received a preparation based on bentonite clay inside 
- 10 days (1 dose three times a day) Evaluation of the effectiveness of treatment was carried out one month after the start of 
treatment. Conclusion: The treatment carried out in both groups was accompanied by positive dynamics in most of the diseaseʹs 
symptoms. But a significant advantage was observed in the second group, where the normalization of cholestatic and dyslipidemic 
syndromes was established, that is, the effect on the pathogenetic links of the progression of NAFLD was proved. The results 
obtained confirm the practicality of using the drug with bentonite in the complex treatment of CHC patients with concomitant 
NAFLD. 
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Introduction 
Modern scientific research is based on an in-depth study of 
the pathogenetic links of various chronic diseases of internal 
organs and the subsequent formation of adequate therapy 
regimens. The issue of treatment of patients with comorbid 
conditions is fundamental. The combination of nosological 
forms can cause disease progression, early complications, 
and correction of therapeutic measures. Among the diffuse 
liver diseases that are most often combined, there is chronic 
viral hepatitis C (CHC) with non-alcoholic fatty liver disease 
(NAFLD) (1, 2). 
NAFLD acts as the main comorbid factor in the development 
of liver damage caused by CHC. This interaction is in a 
shorter time the appearance and progression of fibrosis, from 
initial to advanced stages. On the one hand, the hepatitis C 
virus itself can cytotoxically lead to direct liver damage, 
trigger a genotype-specific way or indirectly, through the 
insulin pathway, to develop fatty liver damage. On the other 
hand, the presence of such risk factors as insulin resistance, 
diabetes mellitus, obesity, intestinal dysbiosis, and 
epigenomic breakdowns lead to the independent formation of 
NAFLD, which aggravates the course of the necrobiotic 
process in the liver tissue and the progression of fibrosis, 
which remains relevant even in patients who have completed 
the course antiviral therapy (AVT) and achieved sustained 
virological response (SVR) (3, 4). 
Studies in the field of assessing the factors of interaction 
along the "intestine-liver" axis show that a targeted effect on 
various elements of this pathophysiological vector, including 
the impact on the qualitative and quantitative composition of 
the intestinal microflora, can slow down the progression of 
fibrosis in chronic liver diseases and improve the prognosis 
for the patient. (5, 6). 
Modern studies of human microflora suggest the central role 
of microbiota and impaired intestinal permeability in the 
development of NAFLD; however, to establish exact 
pathogenetic mechanisms, it is necessary to continue 
research in this direction (7, 8). In this aspect, the intestinal 
microfloraʹs pharmacological modeling may be a promising 
therapeutic strategy in diffuse liver diseases such as NAFLD 
(9, 10). 
Returning to comorbidity as a potential risk factor for further 
progression of fibrosis in patients after achieving a sustained 
virological response (SVR), it should be noted that there are 
limited opportunities in the field of treatment of these 
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conditions. For example, the European Association for the 
Study of the Liverʹs  clinical guidelines indicates the need to 
prescribe drug therapy for NAFLD in patients who have 
either signs of NASH in the presence of fibrosis F2 or higher 
or the risk of disease progression. Currently, only vitamin E 
and pioglitazone are recommended (11). Several new drugs 
for NAFLD treatment continue to remain at various stages of 
clinical trials (12, 13). 
Given the above, it becomes evident that the use of only 
antiviral therapy in this category of patients will not solve 
NAFLD  problem. In this regard, the treatment of patients 
with CHC and NAFLD should be comprehensive and 
consistent. 
Considering that today modern science recognizes the 
essential role of the intestinal microbiota in the occurrence 
and progression of hepatic steatosis to steatohepatitis, it 
seems interesting to study the state of the intestinal 
microbiota (their qualitative and quantitative state) in 
patients with NAFLD and CHC, as well as the effectiveness 
of drinking a drug based on bentonite clay. - "Smectoite 
omega". The basis for this drugʹs use of was preliminary 
complex experimental studies, which found that a solution of 
bentonite clays has ion-exchange, colloidal, absorption 
properties and promotes the elimination of exo- and 
endogenous toxic substances from the body (14, 15). 
That is why we carried out our own experimental and clinical 
studies, the purpose of which was to study the effectiveness 
of taking a suspension of bentonite in rats with a model of 
NAFLD, and the subsequent substantiation of the 
advisability of using a drug based on bentonite in the 
complex treatment of patients with CHC with concomitant 
NAFLD. 
Materials and methods. The study included two stages - 
experimental and clinical Experimental studies were carried 
out following existing guidelines and legal documents (16). 
Forty white Wistar rats were divided into three groups. 
Group 1 consisted of intact animals - the control group (16 
rats), which received a regulal diet and had free access to 
drinking bowls with tap water, Group 2 (12 rats) consisted of 
animals with the NAFLD model. Group 3 (12 rats) consisted 
of animals with the NAFLD model, who received a course of 
bentonite clay (2.5% aqueous solution) from day 30. The 
solution was injected into the esophagus with a soft probe 
with an olive, at a dose of 1% of the animal's body weight, 
once a day, for 12 days. 
According to its chemical composition, the water extract of 
bentonite clay of bentonite is a liquid phase of bentonite and 
consists of salts dissolved in water. The amount of dissolved 
salts is 0.30%, the bulk of which is represented by 
bicarbonate ions (0.15%), sodium and potassium ions, sulfate 
ions (0.06%), calcium ions, and chloride ions (0.04 %). 
The experiment lasted 42 days. To reproduce the NAFLD 
model, animals of groups 2 and 3 received, in addition to the 
standard diet (complete feed and grain mixture in an amount 
of 20 g), 5 g of beef fat rubbed with 10 g of white crackers 
per 1 animal and consumed only 10% fructose solution as a 
drink on distilled water. On the twentieth day, animals of 2 
and 3 groups were injected with CCl4 at the rate of 0.1 ml 
per 200 g of body weight. Upon completion of the study, the 
animals were removed from the experiment under ether 
anesthesia. A piece of liver was prepared from the rats, than 
it was passed through alcohols of increasing concentration 
and poured into celloidin. Subsequently, histological sections 
were prepared, stained with hematoxylin-eosin, and 
microscopic studies of structural changes in the liver were 
carried out. 
In the blood serum, the activity of transamination enzymes, 
alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), the activity of Na+/ K+ dependent 
ATPase, and Mg2+/Ca2+ dependent ATPase in the liver tissue 
homogenate (providing the energy supply of cells), 
indicators of pigment metabolism - total bilirubin and its 
fractions; determined the content of total protein and its 
fraction (albumins, α1-, α2-, β-, γ-globulins), the content of 
urea, creatinine. The state of the antioxidant system (AOS) 
was investigated by the activity of catalase, the state of the 
prooxidant system/peroxidative oxidative lipids (LPO) - by 
the content of malondialdehyde (MDA). 
The level of glucose and triglycerides was also determined in 
blood serum. The techniques used in the research are 
published in the guidelines (17, 18). The data obtained were 
compared with the corresponding indicators of group 1 of 
rats. Statistical processing of data was carried out using the 
programs for biomedical research Statistica. According to the 
Student's tables (p <0.05), significant changes were 
considered those within the confidence limits. 
The clinical study used anamnestic and clinical methods. 
Evaluated: the severity of pain, dyspeptic, asthenic 
syndromes, studied general clinical and biochemical blood 
parameters, including lipid metabolism and the level of 
adipocytokinins. Insulin resistance (IR) was assessed 
according to the HOMA index. Ultrasonographic studies 
(ultrasound) of the digestive organs and bacteriological 
examination of feces were carried out. The generally 
accepted variation statistics methods processed the results 
obtained, the mean values, their errors, and the Fischer-
Student test of reliability were calculated. 
The study was carried out on 40 patients with CHC 
(genotype 1b in the phase of replication, minimal and 
moderate degrees of activity) with concomitant NAFLD. In 
all the examined patients, NAFLD was represented by non-
alcoholic steatohepatitis of minimal activity. Among the 
patients, women predominated, the average age was (52.67 ± 
2.14) years. All patients completed a 3-month course of AVT 
(sofosbuvir (400 mg) and ledipasvir (90 mg)) and received 
an SVR 12 weeks after completion of treatment. 
The patients were divided into two groups. 1 (control) group 
(20 people) received the basic complex of treatment (diet 
therapy, dosed physical activity), patients of 2 groups (20 
people, the main group) additionally received inside the drug 
based on bentonite clay "Smektovit omega" - 10 days (1 dose 
three times a day). Evaluation of the effectiveness of 
treatment was carried out one month after the start of 




"Smektovite omega" in 1 dose (10 g) contains bentonite4 - 
490 mg, sodium - 10 mg, flaxseed oil - 500 mg, wheat germ 
oil - 500 mg, drinking water - 8.5 sm3. 
Results and discussion. In rats of group 2, microscopic 
examination revealed the preservation of the lobular 
organization of the parenchyma. In a significant number of 
hepatocytes, lipid vacuoles of multiple dimensions are 
observed. The inter-girder spaces are expanded, Kupffer 
cells with rounded nuclei. Between the lobules and in some 
of them, homogeneous inclusions of various sizes with 
eosinophilic coloration are observed. In the study of 
metabolic parameters, a significant increase in ALT activity, 
and a decrease in AST activity are determined, which 
indicates a violation of the flow and balance of 
transamination processes (Table 1). 
It can be considered that these changes indicate a violation of 
the permeability of cell membranes. The amount of bilirubin 
significantly increases, while the ratio of its fractions slightly 
changes (the content of direct bilirubin increases), which 
indicates a decrease in the function of bile formation and 
detoxification of the liver. The amount of total protein 
significantly decreases; that is, protein synthesis in the liver 
is suppressed. 
The content of proteins is also changing: the content of α2-, 
ß- and γ-globulins significantly decreases, the content of 
albumin and α1-globulin does not change reliably; that is, 
there is not only a change in the intensity of protein synthesis 
but also its imbalance. A significant increase in the activity 
of Mg2 +/Ca 2+-ATPase and a decrease of Na+/K+ -ATPase 
were found, which indicates an imbalance in the activity of 
transmembrane transport. The power supply of Mg2+ and 
Ca2+ pumps is increased. The results obtained suggest that 
the used model of NAFLC causes dystrophic changes in the 
liver parenchyma with the accumulation of lipid inclusions, 
which are caused by systemic metabolic disorders. 
The need for these ions to ensure the vital activity of cells 
increases significantly. A significant increase in the MDA 
content and a decrease in catalase activity were revealed. 
Consequently, the LPO/AOD systemʹs activity is 
unbalanced, which creates conditions for damage to cell 
membranes. An increase in the content of glucose and 
triglycerides was found, which indicates the inhibition of the 
intensity of carbohydrate and lipid metabolism and, 
consequently, the deposition of excess lipid inclusions in 
hepatocytes. 
Table 1. Dynamics of the main biochemical parameters in 
experimental animals under conditions of reproduction of 
the NAFLD model with internal course intake of bentonite 
suspension, (M ± m) 
Note: * - significant changes (p <0.05) are calculated in 
comparison between 1 and 2 groups; ** - significant 
changes (p <0.05) were calculated in comparison between 
groups 1 and 3. 
In rats of group 3, microscopic examination showed that 
the parenchymaʹs local organization is preserved, the 
hepatocytes are the same, of average size. Their cytoplasm 
is homogeneous, weakly basophilic. Hepatocytes on 2/3 of 
the area of the lobules are collected in beams. On the 
periphery of the lobule, the separation of the beams is 
difficult. Interbeam spaces are widened, Kupffer cells with 
small oval nuclei. 
In some lobules, single hepatocytes with vacuoles of medium 
or small sizes are found. The positive effect on the state of 
metabolic parameters in rats of group 3 is given in detail in 
Table 1. The activity of ALT and AST recovered to the 
control level. As a result of these changes, the de Ritis index 
differs little from the indexe of intact animals, that is, signs 
of damage to hepatocyte membranes disappear, lipoprotein 
metabolism is restored, and detoxification processes are 
approaching normal. 
Positive protein metabolism changes were revealed: the 
content of total protein in the blood almost reaches the 
normal level, and the protein fractions are practically 
restored. The content of simple proteins (albumin) increases, 
while the range of more complex proteins (globulins) 
remains less than control. 
A positive trend was established in terms of the indicators of 
the LPO/AOD system: the content of MDA, the final LPO 
product, returns to the target figures, and the catalase activity 
is restored. This characterizes the improvement of the 
conditions for cell membranesʹ functioning and has a positive 
effect on vital processes. The activity of Na+/K+ -ATPase is 
restored. The activity of Mg2+/Ca2+ -ATPase remains less 
than in control, but the imbalance of their activity decreases, 
which can be considered a tendency to improve 
transmembrane transport. 
The normalization of the activity of Mg2+/Ca2+ -ATPase, 
together with an improvement in the of the membranesʹ state 
due to the restoration of the LPO / AOD system, suggests 
that the supply of Mg2+ and Ca2+ on the membranes is 
restored. In parallel, there is a decrease in pathological 
changes in lipid and carbohydrate metabolism. Thus, the 
internal course administration of a suspension of bentonite in 
rats with the NAFLD model reduces the metabolic changes 
of a pathological nature inherent in this disease. 
Indexes 1st group 2nd group 3rd group 
МDА, nmol/(min×mg) 5,94 ± 0,21 7,49 ± 0,30* 5,87 ± 0,34 
Catalase, % 76,70 ± 1,52 72,42 ± 1,57* 77,06 ± 2,25 
AST, mkmol/l×h 133,09± 4,68 158,05± 3,47* 140,01 ± 2,78 
ALT,  mkmol/l×h 278,84± 6,57 252,66± 5,11* 266,71 ± 7,00 
De Ritis Index, c.u. 2,10 ± 0,07 1,59 ± 0,05* 1,90 ± 0,04** 
Total bilirubin,  mkmol/l 5,79 ± 0,22 6,98 ± 0,31* 5,04 ± 0,32 
Bilirubin direct, mkmol/l 1,98 ± 0,32 2,84 ± 0,05* 1,72 ± 0,06 
Bilirubin indirect, kmol/l 3,81 ± 0,51 4,14 ± 0,39 3,32 ± 0,24 
Total protein , g/l 68,70 ± 2,74 45,79 ± 1,35* 51,38± 2,49** 
Albumin,  g/l 25,80 ± 1,88 22,01 ± 0,59 26,03 ± 1,40 
α-1 Globulin ,  g/l 8,28 ± 0,86 7,19 ± 1,64 7,47 ± 0,56 
α-2 Globulin ,  g/l 10,70 ± 2,20 4,20 ± 0,19* 6,01 ± 1,20** 
β-  Globulin,  g/l 11,82 ± 1,79 6,21±0,24* 8,90 ± 1,80 
γ-  Globulin,  g/l 11,10 ± 0,73 6,19±0,23* 9,07 ± 1,25 
Glucose,  mmol/l 5,11 ± 0,22 6,32 ±0,33* 5,45 ± 0,29 
Triglycerides,  mmol/l 1,10 ± 0,06 1,72 ± 0,05* 1,54 ± 0,08** 
Mg2+/Ca2+-ATPase,  
Р/h×·mg  protein 9,11 ± 0,93 11,75 ± 0,67* 10,14 ± 0,27 
Na+/K+-TPase, Р/h×mg 




The obtained results of experimental studies have proved the 
feasibility of using a bentonite solution in animals with a 
model of NAFLD, which became the basis for the use of the 
drug "SMEKTOVIT omega" in clinical trials. 
A low-symptom course characterized the clinical picture of 
NAFLD in the studied patients. Only a third of the patients 
were concerned about pain syndrome (severity or pain in the 
right hypochondrium, pain on palpation of this area). The 
majority of patients (62.50%) presented complaints 
characterizing intestinal dyspepsia (flatulence, increased gas 
production), which were more associated with concomitant 
disorders of the microflora of the large intestine. Complaints 
describing asthenic syndrome (weakness, increased fatigue, 
decreased performance) were identified in 35.0% of the 
surveyed. The overwhelming majority of patients (82.50%) 
have overweight (BMI) or obesity grade I-II. BMI is equal 
on average (31.97 ± 1.15 kg/m2). 
A biochemical study revealed an increase in total bilirubin 
level due to its indirect fraction in 35.0% of patients, the 
level of alkaline phosphatase, and gam-glutamate transferase 
up to 1.5 N - in 32.5%. The cytolytic syndrome was found in 
17.5% of the examined patients. Lipid metabolism disorders 
were characterized by an increase in the level of total 
cholesterol (TC) on average to (6.65 ± 0.18) ng/ ml, β-
lipoproteins - (66.21 ± 2.13) units, triglycerides - (3.15 ± 
0.12) mmol/l, LDL on average to (4.19 ± 0.27) ng/ml, 
decrease in HDL level on average in the group to (1.33 ± 
0.15) ng/ml. 
The atherogenic coefficient averaged (4.59 ± 0.33) units. 
When studying the carbohydrate metabolism parameters, the 
blood serum glucose level averaged in the group (5.86 ± 
0.39) mmol/l. The insulin concentration was slightly 
increased and averaged (19.24 ± 0.97) μU / ml. The HOMA 
index was (4.52 ± 0.43) units, which indicates a pronounced 
insulin resistance in the examined patients. The level of 
leptin in patients was increased and averaged (29.12 ± 3.52) 
ng/ml, the level of adiponectin was decreased and averaged 
(12.16 ± 1.85) ng/ml. 
According to the bacteriological study of feces for dysbiosis, 
before treatment, 100% of the examined patients were found 
to have quantitative and qualitative changes in the colon 
microflora composition. Thus, in 65.0% of patients, grade II 
colon dysbiosis was diagnosed, in 20.0% of patients - grade I 
colon dysbiosis, in 15.0% - grade III colon dysbiosis. In 
70.0% of patients, a significant decrease in the number of 
bifidobacteria was determined, in 55.0%, to reduce of the 
number of lactobacilli. 
Against the background of a decrease in the total number of 
esherichia, a reduction of  bifidobacteria and lactobacilli was 
diagnosed - 65.0% of cases. Simultaneously, the decline in 
the total number of esherichia was accompanied by the 
appearance among them of hemolyzing (40.0%) and lactose-
negative (25.0%) species of E. coli, that is, microorganisms 
with opportunistic and pathogenic properties. In 45.0% of 
patients, pathogenic and opportunistic microorganisms were 
identified in the form of St. aureus (10.0%), clostridium 
(10.0%), Proteus Vulgaris (5.0%), fungi of the genus 
Candida (20.0%). 
The results of the ultrasound examination in 100% of 
patients showed sonographic signs of hepatic steatosis 
(diffuse increase in the "brightness" of the hepatic 
parenchyma, distal attenuation of the echo signal, blurred 
vascular pattern, its "blurring"), hepatomegaly was detected 
in 67.5% of patients. 
Analysis of the treatment results, carried out a month later, 
showed an improvement in the diseaseʹs clinical course, 
mainly in patients of group 2. 
It should be specially noted a positive effect on the 
elimination of signs of intestinal dyspepsia (flatulence, gas 
formation) in patients of the main group, in contrast to the 
control group, where no significant changes occurred (p> 
0.5). Only in the main group of patients was a significant 
positive effect determined elimination of manifestations of 
asthenic syndrome (p <0.001) - general weakness, rapid 
fatigue. 
Under the influence of this treatment complex, an exact 
positive effect was revealed in eliminating the manifestations 
of pain syndrome; at the end of treatment, only 5.0% of the 
examined main group of patients complained of pain in the 
right hypochondrium. In contrast, signs of pain syndrome 
remained in 15.0% of patients in the control group. 
In all examined patients who had an increased BMI at the 
beginning of treatment, a significant (p <0.001) decrease in 
body weight was determined at the end of treatment; the 
average BMI in the group was (25.89 ± 1.07) kg/m2. 
A biochemical study demonstrated a significant (p <0.05) 
elimination of a cytolytic syndromeʹs  signs in all examined 
patients. Normalization of total bilirubin level (p <0.01) and 
markers of cholestasis (p <0.05) was determined only in 
patients of group 2. Also, patients in group 2 showed a 
significant decrease in the concentration of total cholesterol 
(p <0.01), triglycerides (p <0.05), β-lipoproteins (p <0.01), 
LDL (p <0.05), as well as a tendency to an increase in HDL 
(p> 0.05), in contrast to patients of group 1, in whom the 
changes were insignificant (p> 0.5). Also, in patients of 
group 2, significant changes in carbohydrate metabolism 
were determined, which were characterized by positive 
dynamics of insulin resistance according to the HOMA index 
(p <0.05). 
Positive dynamics in group 2 characterized the change in the 
level of adipocytokines. Thus, the level of adiponectin 
significantly increased and averaged (22.0 5 ± 2.12) ng/ml (p 
<0.05), and the change in the level of leptin was 
characterized by a downward trend, which averaged over the 
group (15.73 ± 3.77) ng/ml (p> 0.05). 
Bacteriological examination of feces showed a significant 
correction of dysbiotic disorders in the colon in patientsʹmain 
group. At the end of treatment, most patients were diagnosed 
with a significant increase in the concentration of 
bifidobacteria (p <0.001), lactobacilli (p <0.001), the total 
number of escherichia (p <0.001). The number of 
microorganisms of pathogenic microflora also significantly 




hemolyzing and lactose-negative properties decreased (p 
<0.001), St. aureus (p <0.05), Proteus Vulgaris (p <0.05), 
fungi of the genus Candida (p <0.05), clostridium (p <0.05). 
No significant changes in the ultrasound picture of the liver 
were observed. However, one-third of patients in group 2 
showed an improvement in the organʹs visualization, a 
decrease in the acoustic density of the liver parenchyma, and 
an improvement in the passage of an ultrasound signal into 
its deep layers. 
Comparative analysis between patients of the 1st control and 
2nd group indicates a greater therapeutic efficiency of the 
therapeutic complex with the a preparation based on 
bentonite clay. 
Conclusions 
1. Under the influence of a course intake of a suspension of 
bentonite, a decrease in the manifestations of lipid 
degeneration of hepatocytes was microscopically established. 
Also, the restoration of carbohydrate metabolism indicators, 
detoxification, bile-forming, bile-excreting, and protein-
synthesis functions of the liver and restoration of energy 
supply of transmembrane transport was determined. 
2. The complex application of the Mediterranean diet, 
physical activity, bentonite suspension contributes to reliable 
(p <0.001) elimination of clinical signs of NAFLD, a 
significant decrease in body weight (p <0.001), 
normalization of the functional state of the liver, especially 
lipid profile (p <0.001), reliable ( p <0.001) correction of the 
quantitative and qualitative composition of the colon 
microflora, restoration of adiponectin secretion and the 
ultrasound picture of the liver. 
3. Complex rehabilitation with the use of a preparation based 
on bentonite clay "Smectoite omega" contributed to the 
favorable dynamics of the clinical course of the disease, 
improvement of the functional state of the liver, 
normalization of lipid metabolism, decrease in insulin 
resistance, restoration of the intestinal microbial landscape, 
restoration of adiponectin secretion - key pathogenetic 
factors in the formation and progression of non-alcoholic 
fatty liver disease 
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